IRIS Institutional Research Information System - AIR Archivio Istituzionale della Ricerca

PERSONENI, NICOLA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 2.007
NA - Nord America 1.837
AS - Asia 1.318
SA - Sud America 161
AF - Africa 28
OC - Oceania 12
Continente sconosciuto - Info sul continente non disponibili 3
Totale 5.366
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.803
GB - Regno Unito 675
DE - Germania 500
CN - Cina 484
SG - Singapore 413
SE - Svezia 275
HK - Hong Kong 168
IT - Italia 133
BR - Brasile 117
RU - Federazione Russa 116
IE - Irlanda 71
FR - Francia 68
IN - India 60
NL - Olanda 35
VN - Vietnam 34
FI - Finlandia 33
JP - Giappone 28
KR - Corea 28
UA - Ucraina 26
CA - Canada 22
ID - Indonesia 22
TR - Turchia 21
DK - Danimarca 17
AR - Argentina 15
AU - Australia 10
BE - Belgio 9
AT - Austria 8
BD - Bangladesh 8
EC - Ecuador 8
GR - Grecia 8
IQ - Iraq 8
ZA - Sudafrica 8
ES - Italia 7
MX - Messico 7
CO - Colombia 6
PK - Pakistan 6
PH - Filippine 5
PY - Paraguay 5
RO - Romania 5
SA - Arabia Saudita 5
TW - Taiwan 5
CI - Costa d'Avorio 4
JO - Giordania 4
UZ - Uzbekistan 4
VE - Venezuela 4
BO - Bolivia 3
CH - Svizzera 3
ET - Etiopia 3
KE - Kenya 3
MA - Marocco 3
PL - Polonia 3
BA - Bosnia-Erzegovina 2
CL - Cile 2
DO - Repubblica Dominicana 2
EG - Egitto 2
EU - Europa 2
HR - Croazia 2
IL - Israele 2
IR - Iran 2
LB - Libano 2
MY - Malesia 2
NO - Norvegia 2
NZ - Nuova Zelanda 2
PT - Portogallo 2
TH - Thailandia 2
TN - Tunisia 2
AL - Albania 1
AN - Antille olandesi 1
AP - ???statistics.table.value.countryCode.AP??? 1
BG - Bulgaria 1
BZ - Belize 1
CZ - Repubblica Ceca 1
DZ - Algeria 1
GA - Gabon 1
HU - Ungheria 1
IM - Isola di Man 1
JM - Giamaica 1
KG - Kirghizistan 1
KH - Cambogia 1
KZ - Kazakistan 1
MK - Macedonia 1
OM - Oman 1
PE - Perù 1
RS - Serbia 1
SN - Senegal 1
SY - Repubblica araba siriana 1
Totale 5.366
Salva come PNG Salva come JPEG
Città #
Southend 616
Frankfurt am Main 369
Singapore 215
Chandler 211
Ashburn 210
Hong Kong 160
Fairfield 155
Seattle 137
Beijing 108
Wilmington 100
Princeton 81
Woodbridge 72
Dublin 71
Houston 67
Milan 60
Council Bluffs 47
Ann Arbor 46
Dallas 46
Cambridge 42
Los Angeles 42
Nanjing 42
Andover 30
Des Moines 29
Bengaluru 26
Buffalo 26
Guangzhou 26
Dearborn 25
New York 24
Moscow 23
Santa Clara 23
Munich 21
Shanghai 21
Jakarta 20
Hefei 19
Phoenix 19
Redwood City 15
Columbus 14
Cangzhou 13
Tokyo 13
Hangzhou 12
Shenyang 12
São Paulo 12
The Dalles 12
Chicago 11
Eitensheim 11
San Diego 11
Toronto 11
Bitonto 10
Frederiksberg 10
Boardman 9
Changsha 9
Ho Chi Minh City 9
Silver Spring 9
Tianjin 9
Istanbul 8
Mountain View 8
Nuremberg 8
Seoul 8
Brussels 7
Jinan 7
Zhengzhou 7
Brasília 6
Brooklyn 6
Hebei 6
Jiaxing 6
Mumbai 6
Nanchang 6
Belo Horizonte 5
Boston 5
Helsinki 5
Johannesburg 5
Kunming 5
Abidjan 4
Amman 4
Berlin 4
Chennai 4
Dhaka 4
Fuzhou 4
Guayaquil 4
Lauterbourg 4
Manila 4
Montreal 4
Ningbo 4
Quanzhou 4
Shenzhen 4
Baghdad 3
Canoas 3
Denver 3
Düsseldorf 3
Grafing 3
Hanoi 3
Lahore 3
London 3
Madrid 3
Orem 3
Quito 3
Redmond 3
Taipei 3
Tashkent 3
Yubileyny 3
Totale 3.652
Salva come PNG Salva come JPEG
Nome #
Fatal Infusion Reaction to Cetuximab : The Need for Predictive Risk Factors and Safer Patient Selection 247
KRAS mutation in lung metastases from colorectal cancer : Prognostic implications 246
Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma. 242
ARQ 087, an oral pan- fibroblast growth factor receptor (FGFR) inhibitor, in patients (pts) with advanced and/or metastatic intrahepatic cholangiocarcinoma (iCCA) 233
Activity and safety of NGR-hTNF, a selective vascular-targeting agent, in previously treated patients with advanced hepatocellular carcinoma 231
Can stereotactic body radiation therapy be a viable and efficient therapeutic option for unresectable locally advanced pancreatic adenocarcinoma? Results of a phase 2 study 214
Tumor and circulating biomarkers in patients with second-line hepatocellular carcinoma from the randomized phase II study with tivantinib 185
A phase II randomized dose escalation trial of sorafenib in patients with advanced hepatocellular carcinoma 181
Stereotactic Ablative Radiotherapy (SABR) in inoperable oligometastatic disease from colorectal cancer : a safe and effective approach 181
Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study. 177
A randomized, multicenter, phase II study of vandetanib monotherapy versus vandetanib in combination with gemcitabine versus gemcitabine plus placebo in subjects with advanced biliary tract cancer : the VanGogh study 175
FOLFIRI and Cetuximab Every Second Week for First-Line Treatment of KRAS Wild-Type Metastatic Colorectal Cancer According to Phosphatase and Tensin Homolog Expression : a Phase II Study 173
Prognostic value of the neutrophil-to-lymphocyte ratio in the ARQ 197-215 second-line study for advanced hepatocellular carcinoma 167
Molecular determinants of outcome in sorafenib-treated patients with hepatocellular carcinoma 167
Standardisation of EGFR FISH in colorectal cancer: Results of an international interlaboratory reproducibility ring study 163
Diagnostic accuracy of 11C-choline PET/CT in comparison with CT and/or MRI in patients with hepatocellular carcinoma 158
Epidermal growth factor receptor gene copy number in esophageal cancer and outcome prediction to gefitinib : does intratumoral heterogeneity matter? 154
Hepatocellular Carcinoma : A Global Disease in Need of Individualized Treatment Strategies 148
Achievements in systhemic therapies in the pre-genomic era in metastatic breast cancer 148
Usefulness of alpha-fetoprotein response in patients treated with sorafenib for advanced hepatocellular carcinoma 138
Assessment of HER2 status in patients with gastroesophageal adenocarcinoma treated with epirubicin-based chemotherapy: heterogeneity-related issues and prognostic implications 136
Tivantinib : a new promising mesenchymal–epithelial transition factor inhibitor in the treatment of hepatocellular carcinoma 120
Clinical results of stereotactic body radiotherapy (SBRT) in the treatment of isolated local recurrence of pancreatic cancer after R0 surgery : a retrospective study 116
Outcome prediction to erlotinib in gastroesophageal adenocarcinomas : can we improve epidermal growth factor receptor and phospho-AKT testing? 116
Advanced colorectal liver metastases and surgery after preoperative chemotherapy : is response-based selection enough? 111
Clinical Usefulness of EGFR Gene Copy Number as a Predictive Marker in Colorectal Cancer Patients Treated with Cetuximab : A Fluorescent In situ Hybridization Study 110
The role of hepatic metastases and pulmonary tumor burden in predicting survival after complete pulmonary resection for colorectal cancer 109
A Comparative Study of Methyl-BEAMing and Droplet Digital PCR for MGMT Gene Promoter Hypermethylation Detection 97
HER-2/neu amplification by fluorescence in situ hybridization in cytologic samples from distant metastatic sites of breast carcinoma 96
Phase III trial comparing protracted intravenous fluorouracil infusion alone or with yttrium-90 resin microspheres radioembolization for liver-limited metastatic colorectal cancer refractory to standard chemotherapy 90
Hepatic intra-arterial injection of Yttrium-loaded microspheres for liver metastasis secondary to colorectal cancer: best soups are sometimes made from old recipes 87
Biomarkers in hepatocellular carcinoma - Letter 86
Evaluation of HER-2/neu amplification and other biological markers as predictors of response to neoadjuvant anthracycline-based chemotherapy in primary breast cancer: the role of anthracycline dose intensity 85
Tivantinib for second-line treatment of advanced hepatocellular carcinoma : a randomised, placebo-controlled phase 2 study 83
Tivantinib for hepatocellular carcinoma 81
Correlation between the response to cetuximab alone or in combination with irinotecan and the activated/phosphorylated epidermal growth factor receptor in metastatic colorectal cancer 75
Reply to Y. Pointreau et al 70
Interleukin-2 enhances the natural killer cell response to Herceptin-coated Her2/neu-positive breast cancer cells 67
KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab 65
Sorafenib in Hepatitis C Virus-Negative Patients With Hepatocellular Carcinoma: Don't Throw the Baby Out With the Bathwater! 61
Response prediction to EGFR-targeted therapies in colorectal cancer 55
null 3
Totale 5.647
Salva come PNG Salva come JPEG
Categoria #
all - tutte 15.710
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 15.710
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021254 0 0 0 0 0 24 13 35 24 34 62 62
2021/2022482 56 39 8 46 19 49 43 17 29 39 44 93
2022/2023619 91 105 74 72 48 109 3 35 37 14 25 6
2023/2024497 12 18 14 30 75 17 53 46 21 57 71 83
2024/20251.049 61 120 46 84 59 39 40 89 64 107 66 274
2025/2026869 212 99 193 134 218 13 0 0 0 0 0 0
Totale 5.647